TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03472690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO-SSI
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02544373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP therapy
Description: Positive airway pressure treatment for obstructive sleep apnea

Intervention type: DEVICE
Group type: OTHER
Intervention: PAP therapy
Description: Positive airway pressure treatment for obstructive sleep apnea
Study: NCT03241004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Mask
Description: sleep mask applied for two separate 60-minute periods during anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Mask
Description: sleep mask applied for two separate 60-minute periods during anesthesia
Study: NCT03597282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1
Study: NCT02368795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin 100 mg suppository ten minutes before ERCP
Study: NCT03597282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1
Study: NCT02368795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Sublingual Isosorbide dinitrate 5 mg before ERCP
Study: NCT03597282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD-1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant
Study: NCT02368795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Sublingual Isosorbide dinitrate 5 mg before ERCP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Study: NCT03597282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M
Description: monoclonal agonist antibody against CD40

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M
Description: monoclonal agonist antibody against CD40

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: monoclonal antibody against CTLA4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: monoclonal antibody against CTLA4
Study: NCT01927042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHOs plus TAU
Description: A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
Study: NCT02368795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's lactate
Description: IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
Study: NCT00468403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
Study: NCT05025696

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blacksoap(R)
Description: Blacksoap(R)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blacksoap(R)
Description: Blacksoap(R)
Study: NCT03254355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: 12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
Study: NCT02231268

Intervention type: DRUG
Intervention: Gladem
Study: NCT04208087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-722
Description: SI-722 will be intravesically instilled.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravesically instilled.
Study: NCT02450968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01345383

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
Study: NCT02502981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg orally once a day for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: 25mg orally once a day for 40 weeks
Study: NCT01345552

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
Study: NCT03951090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Results of the brief geriatric assessment
Description: Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
Study: NCT02070705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study: NCT03951090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No results of brief geriatric assessments
Description: Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
Study: NCT02201836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One time music therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group music therapy
Study: NCT02412059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Study: NCT02064608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: mTOR inhibitor
Study: NCT02774655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pai APP
Description: prescribed 100 PAI weekly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit APP
Description: prescribed 10000 steps daily
Study: NCT01058941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic acid and fish oil concentrate
Description: Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo LA and placebo oil capsules for 18 months
Study: NCT01494519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with an external ring fixator
Description: Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive fixation with a locked IM nail or plate
Description: Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
Study: NCT03712111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 6 mcg
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 10 mcg
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
Study: NCT02070705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Given IV
Study: NCT01212666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacain
Description: Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
Study: NCT00496145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self-Management Program
Description: small-group self management education program
Study: NCT01871116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER-remote
Description: Web-based weight loss program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed
Description: Pamphlet entitled Aim for a Healthy Weight will be given.
Study: NCT00430560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Description: computer training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: work therapy
Description: opportunity to work in carefully supervised hospital job

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: work therapy
Description: work therapy
Study: NCT01916356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational video
Description: Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
Study: NCT04244188

Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
Study: NCT02865993

Intervention type: OTHER
Group type: OTHER
Intervention: betadine group
Description: Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.

Intervention type: OTHER
Group type: OTHER
Intervention: no betadine group
Description: Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
Study: NCT03051321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wellness toilet system
Description: Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
Study: NCT01237535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteal support with progesterone only
Description: Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteal support with estrogen + progesterone
Description: Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
Study: NCT01668394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Learning and coping arm
Description: Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: Usual care. Teaching style: deductive.
Study: NCT01237535

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Insemination without luteal support
Description: Routine insemination procedure without luteal support
Study: NCT02788968

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI
Study: NCT04011501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Erector spinae block
Description: Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
Study: NCT00937872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg SRT2104 Suspension
Description: Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon-14 radio-labeled SRT2104
Description: Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
Study: NCT01825382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBGStar meter
Description: Subjects will receive iBGStar meter and iPhone to use as meter during the study.
Study: NCT03712111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block
Study: NCT02858557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
Study: NCT01185119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: native glp-1 (7-36)
Description: During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: native glp-1 (7-36)
Description: During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
Study: NCT02858557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet
Description: The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet
Description: The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
Study: NCT03713541

Intervention type: OTHER
Intervention: No intervention
Description: Survey during normal supply.

Intervention type: OTHER
Intervention: No intervention
Description: Survey during normal supply.

Intervention type: OTHER
Intervention: No intervention
Description: Survey during normal supply.